Diabetes drug shows promise against deadly skin cancer
NCT ID NCT01840007
First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This pilot study tested whether metformin, a common diabetes drug, could shrink tumors in 20 people with advanced melanoma that had stopped responding to standard treatments. The goal was to see if the drug could cause partial or complete tumor shrinkage. The study is complete, and results will show if metformin offers a new option for controlling this aggressive cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA (STAGE IIIC NON-RÉSÉCABLE OR NO SURGICALLY CURABLE OR STAGE IV WITH CLASSIFICATION AJCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bahadoran
Nice, Alpes-Maritimes, 06200, France
-
MORTIER Laurent
Lille, Nord, 59000, France
Conditions
Explore the condition pages connected to this study.